PharmaShots’ Key Highlights of Fourth Quarter 2020

The fourth quarter of 2020 contains multiple initiations of clinical trials, big approvals, and numerous deals. COVID-19 related news remains at the peak in this quarter Multiple companies received regulatory bodies EUA for their vaccines and treatments for COVID-19. Initiating with, Regeneron sought the US FDA's EUA for REGN-COV2 Ab combination while Health Canada accelerated…

ByDipanshu DixitJanuary 14, 2021

TOP 20

Top 20 Biopharma Acquisitions of 2018 Based on the Total Deal Value

Biopharma acquisition activity in 2018 shows a significant increase over the previous year. Takeda proved to be on top with the acquisition of Shire among the top 20 acquisitions with a total deal value of $57.17B strengthening its capabilities in gastroenterology- neuroscience- oncology- rare diseases- and plasma-derived therapies. This article is based on the 2018…

ByPrince GiriSeptember 27, 2019

PharmaShots’ Key Highlights of Fourth Quarter 2020

Top 20 Biopharma Acquisitions of 2018 Based on the Total Deal Value

Contact US

OUR INFORMATION

FOLLOW US